Jiangsu Nhwa Pharmaceutical (SHE:002262) said its doxapram hydrochloride injection passed the generic drug quality and efficacy consistency evaluation of China's medical products regulator.
The drug is used to treat respiratory failure, according to a Wednesday filing with the Shenzhen bourse.
Shares of the pharmaceutical company closed 1% higher.